

## Effects of SARS-CoV-2 variant, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections

# Suelen H. Qassim, MBBS MPH<sup>a,b,c</sup>, Hiam Chemaitelly, PhD<sup>a,b,c</sup>, Sawsan AlMukdad, Msc<sup>a,b</sup>, and Laith J. Abu-Raddad, PhD<sup>a,b,c,d</sup>

<sup>a</sup>Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar <sup>b</sup>World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar <sup>c</sup>Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, USA <sup>d</sup>Department of Public Health, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar

#### **Background**

- In 2021, Qatar experienced considerable incidence of SARS-CoV-2 infection that was dominated sequentially by the Alpha, Beta, and Delta variants, followed by a large SARS-CoV-2 Omicron wave that started on December 19, 2021 and peaked in mid-January, 2022.
- The real-time reverse-transcription polymerase chain reaction (RT-qPCR) cycle threshold (Ct) value of a SARS-CoV-2-positive test represents the inverse of viral load. Ct value is used as a proxy for SARS-CoV-2 infectiousness. A low Ct value implies high infectiousness.

#### **Objective**

To investigate the effects of SARS-CoV-2 variant, previous vaccination, and prior infection on infectiousness of SARS-CoV-2 infections during the Alpha, Beta and Delta outbreaks (March 23-November 6, 2021) and during the Omicron outbreak (December 23, 2021-February 20, 2022)

Ascertainment of the Alpha, Beta and Delta variant status was done by RT-qPCR genotyping


A SARS-CoV-2 Omicron infection with the BA.1 subvariant was proxied as an Sgene "target failure" (SGTF). The BA.2 subvariant infection was proxied as a non-SGTF case

### **Methodology**

Coronavirus disease 2019 laboratory testing, vaccination, clinical infection, and demographic data were extracted from the national. federated SARS-CoV-2 databases

The average RTqPCR Ct value of the N, ORF1ab, and S gene targets was used as the dependent variable in all analyses

Linear regression analyses were conducted to estimate associations with the Ct value of RTqPCR-positive tests



of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for support from Qatar Genome Programme and Qatar University Biomedical Research Center for supporting the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, or data interpretation.

#### **Results**

Table 1. Associations with RT-qPCR Ct value among the 18,355 RT-qPCR-genotyped Alpha, Beta, and Delta SARS-CoV-2 infections between March 23 and November 6, 2021.

	RT-qPCR Ct value	Univariable analysis
racteristics	Mean (SD)	β coefficient [95% CI]
RS-CoV-2 variant		
a	23.72 (5.14)	Ref.
oha	27.89 (5.65)	4.17 [3.94, 4.39]
ta	22.31 (5.21)	-1.41 [-1.59, -1.24]
cination status		
vaccinated	23.98 (5.65)	Ref.
e dose	23.93 (5.71)	-0.05 [-0.40, 0.31]
o doses		
months before the RT-qPCR test	24.43 (5.86)	$0.45 \ [0.14, 0.77]$
<6 months before the RT-qPCR test	22.59 (5.40)	-1.39 [-1.63, -1.15]
<9 months before the RT-qPCR test	21.79 (5.12)	-2.19 [-2.66, -1.71]
months before the RT-qPCR test	18.81 (2.22)	-5.17 [-10.68, 0.34]
ee doses		
month before the RT-qPCR test	22.99 (5.40)	-0.99 [-5.92, 3.94]
month before the RT-qPCR test	19.80 (2.97)	-4.18 [-9.69, 1.33]
or SARS-CoV-2 infection		
ver	23.14 (5.51)	Ref.
) days before the study RT-qPCR test	27.65 (4.93)	4.51 [4.27, 4.74]
or infection <sup>b</sup>	25.88 (5.93)	2.74 [1.99, 3.48]

Table 2. Associations with RT-qPCR Ct value among 156,202 individuals with SARS-CoV-2 Omicron infections between December 23, 2021 and February

··		
	RT-qPCR Ct value	Univariable analysis
racteristics	Mean (SD)	β coefficient [95% CI]
cron subvariant		
.1	27.11 (6.60)	Ref.
.2	23.46 (5.82)	-3.65 [-3.73, -3.58]
cination status		
vaccinated	25.38 (6.27)	Ref.
e dose	23.92 (6.05)	-1.46 [-1.82, -1.09]
o doses		
months before the RT-qPCR test	24.69 (6.25)	-0.69 [-0.93, -0.44]
<6 months before the RT-qPCR test	24.07 (6.16)	-1.31 [-1.42, -1.20]
<9 months before the RT-qPCR test	23.43 (5.96)	-1.95 [-2.02, -1.87]
months before the RT-qPCR test	23.47 (5.97)	-1.91 [-2.00, -1.81]
ee doses		
month before the RT-qPCR test	24.98 (6.30)	-0.39 [-0.54, -0.25]
month before the RT-qPCR test	24.21 (6.23)	-1.17 [-1.31, -1.02]
rious SARS-CoV-2 infection		
ver	24.09 (6.16)	Ref.
days before the study RT-qPCR test	29.18 (5.41)	5.09 [4.58, 5.60]
or infection <sup>b</sup>	25.22 (6.07)	1.12 [1.01, 1.23]
PCR Ct value was adjusted for age-group, sex, nationality, SARS-CoV-2 varian	t, reason for RT-qPCR test, RT-qPCR test study-period time,	vaccination status, and prior SARS-CoV-2 infection

<sup>b</sup>Prior infection was defined as an RT-qPCR-positive test that occurred  $\geq$ 90 days before the RT-qPCR-positive test that is included in the study.

### Conclusions

Delta appears substantially more infectious than Beta.

BA.2 subvariant appears substantially more infectious than BA.1 subvariant.

Prior immunity, whether due to vaccination or prior infection, is associated with lower infectiousness of breakthrough infections.



P. O. Box 24144 T: +974-4492-8498 sqa4001@qatar-med.cornell.edu

## Multivariable analysis<sup>a</sup> β coefficient [95% CI] Ref. 2.56 [2.35, 2.78] -4.92 [-5.16, -4.67] Ref. 0.57 [0.26, 0.87] 0.86 [0.59, 1.13] 0.08 [-0.17, 0.32] -0.26 [-0.72, 0.19] -3.23 [-7.89, 1.42] -1.36 [-5.52, 2.79] -1.83 [-6.47, 2.81] Ref. 3.95 [3.73, 4.17] 2.07 [1.42, 2.72] Multivariable analysis<sup>a</sup> β coefficient [95% CI] Ref. -3.53 [-3.60, -3.46] Ref. -0.34 [-0.67, -0.00] 0.23 [0.00, 0.46] -0.05 [-0.15, 0.06] -0.48 [-0.56, -0.40] -0.43 [-0.53, -0.33] 0.86 [0.72, 1.00] 0.28 [0.14, 0.42] Ref. 4.23 [3.77, 4.69] 1.30 [1.20, 1.39]